JARDIANCE 10 MG
EMPAGLIFLOZIN : 10 MG · DIN 02443937 · BOEHRINGER INGELHEIM (CANADA) LTD LTEE
Health Canada status: MARKETED
What is JARDIANCE?
JARDIANCE 10 MG contains EMPAGLIFLOZIN : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02443937, held by BOEHRINGER INGELHEIM (CANADA) LTD LTEE, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 11-Aug-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is JARDIANCE used for?
JARDIANCE (empagliflozin) is indicated for use as an adjunct to diet and exercise to improve glycemic control in adult patients with T2DM for whom metformin is inappropriate due to contraindications or intolerance. JARDIANCE is indicated in adult patients with T2DM to improve glycemic control in combination with metformin, metformin and a sulfonylurea, pioglitazone (alone or with metformin), linagliptin and metformin, basal or prandial insulin (alone or with metformin) when metformin alone or the existing therapy listed above, along with diet and exercise, do not provide adequate glycemic control. JARDIANCE is indicated as an adjunct to diet, exercise and standard care therapy to reduce the incidence of cardiovascular death in patients with T2DM and established cardiovascular disease. JARDIANCE is indicated in adults as an adjunct to standard of care therapy for the treatment of heart failure. JARDIANCE is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular and renal death in adults with chronic kidney disease.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02443937 |
|---|---|
| Brand name | JARDIANCE |
| Generic / active ingredient | EMPAGLIFLOZIN : 10 MG |
| Manufacturer | BOEHRINGER INGELHEIM (CANADA) LTD LTEE |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A10BK03 EMPAGLIFLOZIN |
| AHFS class | 68:20.18 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 11-Aug-2015 |
| Original market date | 2015-08-11 00:00:00 |
How is it stored and handled?
null
How is it supplied?
PVC/aluminium unit dose blisters in cartons containing : 10 x 1 blister card (physician sample for the patients); or 10 x 3 blister cards , or 10 x 9 blister cards (commercial presentation).
What can be used instead?
Other Canadian products sharing ATC code A10BK03 EMPAGLIFLOZIN. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JARDIANCE | 25 MG | TABLET | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | MARKETED | DIN 02443945 |
Who else supplies EMPAGLIFLOZIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. EMPAGLIFLOZIN appears in 101 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.